Stemline was founded in 2003 and acquired by the Menarini Group in 2020, with its global HQ in New York City. At Menarini Stemline^® UK, we are committed to developing a broad pipeline of innovative, transformative therapies in oncology to make a meaningful difference to the lives of patients living with cancer. Our dedicated team works towards addressing complex and unexplored unmet needs, elevating the standards of care in oncology and transforming every life touched by cancer.

Towards the end of 2023, our UKINORD business finalised its renewed vision, further solidifying our commitment to align with the evolving landscape of cancer care.

And our experienced team in the UK is committed to making a difference. Collaborating closely with the healthcare system, we aim to enhance patient outcomes and contribute to advancing cancer care in the UK.